Home > Press Releases > Digital Therapeutics (DTX) Market

Digital Therapeutics (DTX) Market Likely to Surpass ~USD 70 Billion by 2035

Report Code: HC-97053  |  Published in: Oct 2025, By MarketGenics  |  Number of pages: 299
Get PDF
Buy

A significant study discovering the market avenues on, “Digital Therapeutics (DTX) Market Size, Share & Trends Analysis Report by Therapeutic Application (Diabetes Management, Obesity Management, Cardiovascular Diseases, Central Nervous System (CNS) Disorders, Respiratory Diseases, Substance Abuse Disorders, Gastrointestinal Disorders, Musculoskeletal Disorders, Sleep Disorders, Chronic Pain Management), Product Type, Sales Channel, Prescription Type, Patient Age Group, Reimbursement Model, Delivery Mode, Technology, End-users, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035” A holistic view of the market pathways in the Digital Therapeutics (DTX)  market underscores revenue acceleration through three key levers scalable product line extensions, high‑maturity strategic partnerships.

Global Digital Therapeutics (DTX) Market Forecast 2035:

According to the report, the global digital therapeutics (DTx) market is projected to expand from USD 6.6 billion in 2025 to USD 70.4 billion by 2035, registering a CAGR of 26.7%, the highest during the forecast period. Digital therapeutics (DTx) are medical interventions administered using a clinically proven digital platform and are based on software and delivered to prevent, manage, or treat diseases. These solutions are included in the digital therapeutics market and offer structured therapeutic programs that encourage behavioral change, lifestyle change, and adherence to treatment, which in turn enhance patient outcomes.

In contrast to general wellness or fitness apps, DTx products are evaluated and approved by strict clinical procedures and regulatory standards that are needed to guarantee their safety, efficacy, and reliability. They may be used as an independent prescription or with conventional therapies, which is why they become one of the most important elements of the modern and data-driven healthcare delivery.

The market of digital therapeutics is growing in the fields of diabetes, obesity, cardiovascular diseases, mental illnesses, respiratory diseases, and nervous disorders. With the use of technology, real time follow up, and customized feedback, DTx enables patients to be actively involved in their care and provides healthcare professionals with practical data used to make informed decisions. In sum, the digital therapeutics market is the combination of digital health innovation and clinical medicine, which can provide patient-centered, scalable solutions that can change its accessibility, engagement, and long-term health outcomes.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global Digital Therapeutics (DTX) Market

Digital therapeutics market is growing because of the awareness of preventive healthcare, with more patients and healthcare providers putting emphasis on early interventions to manage and prevent chronic diseases. Digital therapeutics (DTx) solutions provide personalized education, live tracking, and formal lifestyle management support to allow the prevention of the disease proactively. The digital therapeutic market helps to improve the health outcomes, decrease the costs of the long-term treatment and improve the level of patient engagement in self-management and general wellness by promoting early care.

The market of digital therapeutics is constrained by interoperability problems because most DTx platforms have problems with seamless integration with existing healthcare IT systems like electronic health records (EHRs) and hospital management software. Such incompatibility may restrict the exchange of data, interfere with clinical processes, and minimize the performance of digital interventions. Addressing these barriers to integration is essential in improving usability, having coordinated care, and motivating more people to adopt digital solutions in therapeutics.

Pediatric and adolescent healthcare is emerging as a promising segment in the digital therapeutics market, with DTx solutions specifically designed to address chronic disease prevention and management in younger populations. these solutions deliver age-specific advice, interaction features and live tracking to encourage healthy habits at an early age. Digital therapeutics can be used to prevent future disease load, promote long-term well-being, and enable children and adolescents to take an active role in their health by concentrating on prevention and early intervention.

Expansion of Global Digital Therapeutics (DTX) Market

“Innovation, pharma demand, and public funding propel the global Digital Therapeutics (DTX) market expansion”

  • The Digital Therapeutics (DTX) market is undergoing remarkable expansion in the world market, which is mostly caused by the continuous innovations in the field of software, artificial intelligence, and mobile health platforms. In June 2025, Hinge Health launched HingeSelect, a high-performance provider network, which will provide unified musculoskeletal (MSK) care by combining Hinge Health digital exercise therapy (using AI) with a curated network of more than 3,300 vetted in-person providers across all 50 U.S. states. HingeSelect also plans to create a gap between digital and real-life MSK care, providing a smooth experience to the members. The network is made to supplement the current health plan models, offering a complete network that will enhance access to high-value care at a lower cost to employers and health plans.
  • Government and insurance incentives can greatly drive the uptake of digital therapeutics (DTx) by offering financial assistance and policies. As an example, he Digital Health Incentive Scheme (DHIS) that was launched within the Ayushman Bharat Digital Mission (ABDM) can be viewed as an example of such governmental efforts. According to this scheme, hospitals, diagnostic labs, and digital health solution providers can receive financial incentives up to 4 crores depending on the number of digital health records generated and connected to Ayushman Bharat Health Account (ABHA) numbers.

Regional Analysis of Global Digital Therapeutics (DTX) Market

  • North America's digital therapeutics (DTX) industry is highly promising due to high healthcare spending, advanced digital infrastructure, and widespread usage of smartphones and wearables. Prescription digital therapeutics are also strongly supported by regulatory agencies such as the FDA, and the reimbursement policies are also favorable, which additionally encourages health care providers and payers. Also, the increase in chronic disease rates, the rise in patient interest in preventive care, and partnerships between technological and pharmaceutical firms are contributing to market expansion in the region. As an example, Pear Therapeutics has created prescription digital therapeutics like reSET and reSET-O substance use disorder that have proven to have quantifiable clinical results and are currently extensively used in the U.S. healthcare system.
  • The Asian Pacific market for digital therapeutics (DTX) is predicted to grow rapidly due to increased digital infrastructure, smartphone and internet usage, and awareness of preventive management. Government support programs, programs of healthcare digitization and associations between local and international DTX providers are additional support programs that increase market adoption. The emerging markets such as China, India, Japan and South Korea are becoming major markets, exploiting the use of technology-based healthcare solutions in enhancing patient outcomes and decreasing the cost of prolonged treatment. All these factors combined make the Asia Pacific region an extremely promising market of digital therapeutics in the next decade. An example is Practo, a healthcare platform in Bengaluru that has greatly grown its digital health practices in Southeast Asia, Middle East, and Africa.

Prominent players operating in the global digital therapeutics (DTX) market are 2Morrow, Akili Interactive, Ayogo Health, Better Therapeutics, Big Health, Biofourmis, Canary Health, Click Therapeutics, Cognoa, Happify Health, Kaia Health, Livongo Health (Teladoc Health), Mango Health, Mindstrong Health, Noom, Omada Health, Pear Therapeutics, Propeller Health (ResMed), Proteus Digital Health, Voluntis (now part of AstraZeneca), Welldoc, and Other Key Players.

The global digital therapeutics (DTX) market has been segmented as follows:

Global Digital Therapeutics (DTX) Market Analysis, By Therapeutic Application

  • Diabetes Management
  • Obesity Management
  • Cardiovascular Diseases
  • Central Nervous System (CNS) Disorders
    • Depression
    • Anxiety
    • Schizophrenia
    • ADHD
    • Others
  • Respiratory Diseases
    • Asthma
    • COPD
    • Others
  • Substance Abuse Disorders
    • Smoking Cessation
    • Alcohol Dependence
    • Opioid Addiction
    • Others
  • Gastrointestinal Disorders
  • Musculoskeletal Disorders
  • Sleep Disorders
  • Chronic Pain Management

Global Digital Therapeutics (DTX) Market Analysis, By Product Type

  • Software Applications
  • Wearable Devices
  • Mobile Applications
  • Web-based Platforms
  • Virtual Reality (VR) Solutions
  • Augmented Reality (AR) Solutions
  • Game-based Therapeutics
  • Chatbot/AI-powered Solutions

Global Digital Therapeutics (DTX) Market Analysis, By Sales Channel

  • Business-to-Business (B2B)
    • Healthcare Providers
    • Employers
    • Payers/Insurance Companies
    • Others
  • Business-to-Consumer (B2C)
    • Direct-to-Patient
    • App Stores
    • Online Platforms
    • Others

Global Digital Therapeutics (DTX) Market Analysis, By Prescription Type

  • Prescription DTx
  • Non-prescription DTx (OTC)

Global Digital Therapeutics (DTX) Market Analysis, By Reimbursement Model

  • Pediatric (0-17 years)
  • Adults (18-64 years)
  • Geriatric (65+ years)

Global Digital Therapeutics (DTX) Market Analysis, By Patient Age Group

  • Insurance Reimbursed
  • Out-of-Pocket
  • Employer-sponsored
  • Government-funded Programs
  • Others

Global Digital Therapeutics (DTX) Market Analysis, By Delivery Mode

  • Standalone DTx Solutions
  • Integrated with Medical Devices
  • Hybrid

Global Digital Therapeutics (DTX) Market Analysis, By Technology

  • Cognitive Behavioral Therapy (CBT) Digital Programs
  • Biofeedback Technology
  • Gamification Technology
  • Telehealth Integration
  • Remote Patient Monitoring
  • Data Analytics & Predictive Modeling
  • AI & ML Integration
  • Blockchain Technology
  • Others

Global Digital Therapeutics (DTX) Market Analysis, by End Use Industry

  • Healthcare Providers
    • Hospitals
    • Clinics
    • Rehabilitation Centers
    • Primary Care Physicians
    • Others
  • Insurance Companies
    • Health Insurance Providers
    • Medicare/Medicaid
    • Private Insurers
    • Others
  • Patients/Individual Consumers
    • Chronic Disease Patients
    • Mental Health Patients
    • Wellness Seekers
    • Others
  • Pharmaceutical Companies
    • Drug Manufacturers
    • Biotech Firms
    • Others
    • Research Institutions
  • Other End-users

Global Digital Therapeutics (DTX) Market Analysis, By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Digital Therapeutics (DTX) Market Outlook
      • 2.1.1. Digital Therapeutics (DTX) Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2025-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Digital Therapeutics (DTX) Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
    • 3.4. Trade Analysis
      • 3.4.1. Import & Export Analysis, 2025
      • 3.4.2. Top Importing Countries
      • 3.4.3. Top Exporting Countries
    • 3.5. Trump Tariff Impact Analysis
      • 3.5.1. Manufacturer
        • 3.5.1.1. Based on the component & Raw material
      • 3.5.2. Supply Chain
      • 3.5.3. End Consumer
    • 3.6. Raw Material Analysis
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Rising chronic disease burden and demand for remote, scalable care
        • 4.1.1.2. Strengthening clinical evidence and regulatory acceptance / integration into care pathways
        • 4.1.1.3. Greater smartphone/internet penetration plus rising payer reimbursement and investment
      • 4.1.2. Restraints
        • 4.1.2.1. Data privacy/security concerns and fragmented regulatory frameworks
        • 4.1.2.2. Low patient engagement/digital literacy and limited clinician reimbursement
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
    • 4.5. Porter’s Five Forces Analysis
    • 4.6. PESTEL Analysis
    • 4.7. Global Digital Therapeutics (DTX) Market Demand
      • 4.7.1. Historical Market Size - in Value (US$ Bn), 2020-2024
      • 4.7.2. Current and Future Market Size - in Value (US$ Bn), 2025–2035
        • 4.7.2.1. Y-o-Y Growth Trends
        • 4.7.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Digital Therapeutics (DTX) Market Analysis, By Therapeutic Application
    • 6.1. Key Segment Analysis
    • 6.2. Digital Therapeutics (DTX) Market Size (Value - US$ Bn), Analysis, and Forecasts, By Therapeutic Application, 2021-2035
      • 6.2.1. Diabetes Management
      • 6.2.2. Obesity Management
      • 6.2.3. Cardiovascular Diseases
      • 6.2.4. Central Nervous System (CNS) Disorders
        • 6.2.4.1. Depression
        • 6.2.4.2. Anxiety
        • 6.2.4.3. Schizophrenia
        • 6.2.4.4. ADHD
        • 6.2.4.5. Others
      • 6.2.5. Respiratory Diseases
        • 6.2.5.1. Asthma
        • 6.2.5.2. COPD
        • 6.2.5.3. Others
      • 6.2.6. Substance Abuse Disorders
        • 6.2.6.1. Smoking Cessation
        • 6.2.6.2. Alcohol Dependence
        • 6.2.6.3. Opioid Addiction
        • 6.2.6.4. Others
      • 6.2.7. Gastrointestinal Disorders
      • 6.2.8. Musculoskeletal Disorders
      • 6.2.9. Sleep Disorders
      • 6.2.10. Chronic Pain Management
  • 7. Global Digital Therapeutics (DTX) Market Analysis, By Product Type
    • 7.1. Key Segment Analysis
    • 7.2. Digital Therapeutics (DTX) Market Size (Value - US$ Bn), Analysis, and Forecasts, By Product Type, 2021-2035
      • 7.2.1. Software Applications
      • 7.2.2. Wearable Devices
      • 7.2.3. Mobile Applications
      • 7.2.4. Web-based Platforms
      • 7.2.5. Virtual Reality (VR) Solutions
      • 7.2.6. Augmented Reality (AR) Solutions
      • 7.2.7. Game-based Therapeutics
      • 7.2.8. Chatbot/AI-powered Solutions
  • 8. Global Digital Therapeutics (DTX) Market Analysis and Forecasts,By Sales Channel
    • 8.1. Key Findings
    • 8.2. Digital Therapeutics (DTX) Market Size (Value - US$ Mn), Analysis, and Forecasts, By Sales Channel, 2021-2035
      • 8.2.1. Business-to-Business (B2B)
        • 8.2.1.1. Healthcare Providers
        • 8.2.1.2. Employers
        • 8.2.1.3. Payers/Insurance Companies
        • 8.2.1.4. Others
      • 8.2.2. Business-to-Consumer (B2C)
        • 8.2.2.1. Direct-to-Patient
        • 8.2.2.2. App Stores
        • 8.2.2.3. Online Platforms
        • 8.2.2.4. Others
  • 9. Global Digital Therapeutics (DTX) Market Analysis and Forecasts, By Prescription Type
    • 9.1. Key Findings
    • 9.2. Digital Therapeutics (DTX) Market Size (Vo Value - US$ Mn), Analysis, and Forecasts, By Prescription Type, 2021-2035
      • 9.2.1. Prescription DTx
      • 9.2.2. Non-prescription DTx (OTC)
  • 10. Global Digital Therapeutics (DTX) Market Analysis and Forecasts, By Patient Age Group
    • 10.1. Key Findings
    • 10.2. Digital Therapeutics (DTX) Market Size (Value - US$ Mn), Analysis, and Forecasts, By Patient Age Group, 2021-2035
      • 10.2.1. Pediatric (0-17 years)
      • 10.2.2. Adults (18-64 years)
      • 10.2.3. Geriatric (65+ years)
  • 11. Global Digital Therapeutics (DTX) Market Analysis and Forecasts, By Reimbursement Model
    • 11.1. Key Findings
    • 11.2. Digital Therapeutics (DTX) Market Size (Value - US$ Mn), Analysis, and Forecasts, By Reimbursement Model, 2021-2035
      • 11.2.1. Insurance Reimbursed
      • 11.2.2. Out-of-Pocket
      • 11.2.3. Employer-sponsored
      • 11.2.4. Government-funded Programs
      • 11.2.5. Others
  • 12. Global Digital Therapeutics (DTX) Market Analysis and Forecasts, By Delivery Mode
    • 12.1. Key Findings
    • 12.2. Digital Therapeutics (DTX) Market Size (Value - US$ Mn), Analysis, and Forecasts, By Delivery Mode, 2021-2035
      • 12.2.1. Standalone DTx Solutions
      • 12.2.2. Integrated with Medical Devices
      • 12.2.3. Hybrid
  • 13. Global Digital Therapeutics (DTX) Market Analysis and Forecasts, By Technology
    • 13.1. Key Findings
    • 13.2. Digital Therapeutics (DTX) Market Size (Value - US$ Mn), Analysis, and Forecasts, By Technology, 2021-2035
      • 13.2.1. Cognitive Behavioral Therapy (CBT) Digital Programs
      • 13.2.2. Biofeedback Technology
      • 13.2.3. Gamification Technology
      • 13.2.4. Telehealth Integration
      • 13.2.5. Remote Patient Monitoring
      • 13.2.6. Data Analytics & Predictive Modeling
      • 13.2.7. AI & ML Integration
      • 13.2.8. Blockchain Technology
      • 13.2.9. Others
  • 14. Global Digital Therapeutics (DTX) Market Analysis and Forecasts, By End-users
    • 14.1. Key Findings
    • 14.2. Digital Therapeutics (DTX) Market Size (Value - US$ Mn), Analysis, and Forecasts, By End-users, 2021-2035
      • 14.2.1. Healthcare Providers
        • 14.2.1.1. Hospitals
        • 14.2.1.2. Clinics
        • 14.2.1.3. Rehabilitation Centers
        • 14.2.1.4. Primary Care Physicians
        • 14.2.1.5. Others
      • 14.2.2. Insurance Companies
        • 14.2.2.1. Health Insurance Providers
        • 14.2.2.2. Medicare/Medicaid
        • 14.2.2.3. Private Insurers
        • 14.2.2.4. Others
      • 14.2.3. Patients/Individual Consumers
        • 14.2.3.1. Chronic Disease Patients
        • 14.2.3.2. Mental Health Patients
        • 14.2.3.3. Wellness Seekers
        • 14.2.3.4. Others
      • 14.2.4. Pharmaceutical Companies
        • 14.2.4.1. Drug Manufacturers
        • 14.2.4.2. Biotech Firms
        • 14.2.4.3. Others
      • 14.2.5. Research Institutions
      • 14.2.6. Other End-users
  • 15. Global Digital Therapeutics (DTX) Market Analysis and Forecasts, by Region
    • 15.1. Key Findings
    • 15.2. Digital Therapeutics (DTX) Market Size (Value - US$ Mn), Analysis, and Forecasts, by Region, 2021-2035
      • 15.2.1. North America
      • 15.2.2. Europe
      • 15.2.3. Asia Pacific
      • 15.2.4. Middle East
      • 15.2.5. Africa
      • 15.2.6. South America
  • 16. North America Digital Therapeutics (DTX) Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. North America Digital Therapeutics (DTX) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Therapeutic Application
      • 16.3.2. Product Type
      • 16.3.3. Sales Channel
      • 16.3.4. Prescription Type
      • 16.3.5. Patient Age Group
      • 16.3.6. Reimbursement Model
      • 16.3.7. Delivery Mode
      • 16.3.8. Technology
      • 16.3.9. End-Users
      • 16.3.10. Country
        • 16.3.10.1. USA
        • 16.3.10.2. Canada
        • 16.3.10.3. Mexico
    • 16.4. USA Digital Therapeutics (DTX) Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Therapeutic Application
      • 16.4.3. Product Type
      • 16.4.4. Sales Channel
      • 16.4.5. Prescription Type
      • 16.4.6. Patient Age Group
      • 16.4.7. Reimbursement Model
      • 16.4.8. Delivery Mode
      • 16.4.9. Technology
      • 16.4.10. End-Users
    • 16.5. Canada Digital Therapeutics (DTX) Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Therapeutic Application
      • 16.5.3. Product Type
      • 16.5.4. Sales Channel
      • 16.5.5. Prescription Type
      • 16.5.6. Patient Age Group
      • 16.5.7. Reimbursement Model
      • 16.5.8. Delivery Mode
      • 16.5.9. Technology
      • 16.5.10. End-Users
    • 16.6. Mexico Digital Therapeutics (DTX) Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Material Type
      • 16.6.3. Packaging Type
      • 16.6.4. Technology Used
      • 16.6.5. Distribution Channel
      • 16.6.6. Product Format
      • 16.6.7. Production Process
      • 16.6.8. End-Users
  • 17. Europe Digital Therapeutics (DTX) Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Europe Digital Therapeutics (DTX) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Therapeutic Application
      • 17.3.2. Product Type
      • 17.3.3. Sales Channel
      • 17.3.4. Prescription Type
      • 17.3.5. Patient Age Group
      • 17.3.6. Reimbursement Model
      • 17.3.7. Delivery Mode
      • 17.3.8. Technology
      • 17.3.9. End-Users
      • 17.3.10. Country
        • 17.3.10.1. Germany
        • 17.3.10.2. United Kingdom
        • 17.3.10.3. France
        • 17.3.10.4. Italy
        • 17.3.10.5. Spain
        • 17.3.10.6. Netherlands
        • 17.3.10.7. Nordic Countries
        • 17.3.10.8. Poland
        • 17.3.10.9. Russia & CIS
        • 17.3.10.10. Rest of Europe
    • 17.4. Germany Digital Therapeutics (DTX) Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Therapeutic Application
      • 17.4.3. Product Type
      • 17.4.4. Sales Channel
      • 17.4.5. Prescription Type
      • 17.4.6. Patient Age Group
      • 17.4.7. Reimbursement Model
      • 17.4.8. Delivery Mode
      • 17.4.9. Technology
      • 17.4.10. End-Users
    • 17.5. United Kingdom Digital Therapeutics (DTX) Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Therapeutic Application
      • 17.5.3. Product Type
      • 17.5.4. Sales Channel
      • 17.5.5. Prescription Type
      • 17.5.6. Patient Age Group
      • 17.5.7. Reimbursement Model
      • 17.5.8. Delivery Mode
      • 17.5.9. Technology
      • 17.5.10. End-Users
    • 17.6. France Digital Therapeutics (DTX) Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Therapeutic Application
      • 17.6.3. Product Type
      • 17.6.4. Sales Channel
      • 17.6.5. Prescription Type
      • 17.6.6. Patient Age Group
      • 17.6.7. Reimbursement Model
      • 17.6.8. Delivery Mode
      • 17.6.9. Technology
      • 17.6.10. End-Users
    • 17.7. Italy Digital Therapeutics (DTX) Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Therapeutic Application
      • 17.7.3. Product Type
      • 17.7.4. Sales Channel
      • 17.7.5. Prescription Type
      • 17.7.6. Patient Age Group
      • 17.7.7. Reimbursement Model
      • 17.7.8. Delivery Mode
      • 17.7.9. Technology
      • 17.7.10. End-Users
    • 17.8. Spain Digital Therapeutics (DTX) Market
      • 17.8.1. Therapeutic Application
      • 17.8.2. Product Type
      • 17.8.3. Sales Channel
      • 17.8.4. Prescription Type
      • 17.8.5. Patient Age Group
      • 17.8.6. Reimbursement Model
      • 17.8.7. Delivery Mode
      • 17.8.8. Technology
      • 17.8.9. End-Users
    • 17.9. Netherlands Digital Therapeutics (DTX) Market
      • 17.9.1. Country Segmental Analysis
      • 17.9.2. Therapeutic Application
      • 17.9.3. Product Type
      • 17.9.4. Sales Channel
      • 17.9.5. Prescription Type
      • 17.9.6. Patient Age Group
      • 17.9.7. Reimbursement Model
      • 17.9.8. Delivery Mode
      • 17.9.9. Technology
      • 17.9.10. End-Users
    • 17.10. Nordic Countries Digital Therapeutics (DTX) Market
      • 17.10.1. Country Segmental Analysis
      • 17.10.2. Therapeutic Application
      • 17.10.3. Product Type
      • 17.10.4. Sales Channel
      • 17.10.5. Prescription Type
      • 17.10.6. Patient Age Group
      • 17.10.7. Reimbursement Model
      • 17.10.8. Delivery Mode
      • 17.10.9. Technology
      • 17.10.10. End-Users
    • 17.11. Poland Digital Therapeutics (DTX) Market
      • 17.11.1. Country Segmental Analysis
      • 17.11.2. Therapeutic Application
      • 17.11.3. Product Type
      • 17.11.4. Sales Channel
      • 17.11.5. Prescription Type
      • 17.11.6. Patient Age Group
      • 17.11.7. Reimbursement Model
      • 17.11.8. Delivery Mode
      • 17.11.9. Technology
      • 17.11.10. End-Users
    • 17.12. Russia & CIS Digital Therapeutics (DTX) Market
      • 17.12.1. Country Segmental Analysis
      • 17.12.2. Therapeutic Application
      • 17.12.3. Product Type
      • 17.12.4. Sales Channel
      • 17.12.5. Prescription Type
      • 17.12.6. Patient Age Group
      • 17.12.7. Reimbursement Model
      • 17.12.8. Delivery Mode
      • 17.12.9. Technology
      • 17.12.10. End-Users
    • 17.13. Rest of Europe Digital Therapeutics (DTX) Market
      • 17.13.1. Country Segmental Analysis
      • 17.13.2. Therapeutic Application
      • 17.13.3. Product Type
      • 17.13.4. Sales Channel
      • 17.13.5. Prescription Type
      • 17.13.6. Patient Age Group
      • 17.13.7. Reimbursement Model
      • 17.13.8. Delivery Mode
      • 17.13.9. Technology
      • 17.13.10. End-Users
  • 18. Asia Pacific Digital Therapeutics (DTX) Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. East Asia Digital Therapeutics (DTX) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Therapeutic Application
      • 18.3.2. Product Type
      • 18.3.3. Sales Channel
      • 18.3.4. Prescription Type
      • 18.3.5. Patient Age Group
      • 18.3.6. Reimbursement Model
      • 18.3.7. Delivery Mode
      • 18.3.8. Technology
      • 18.3.9. End-Users
      • 18.3.10. Country
        • 18.3.10.1. China
        • 18.3.10.2. India
        • 18.3.10.3. Japan
        • 18.3.10.4. South Korea
        • 18.3.10.5. Australia and New Zealand
        • 18.3.10.6. Indonesia
        • 18.3.10.7. Malaysia
        • 18.3.10.8. Thailand
        • 18.3.10.9. Vietnam
        • 18.3.10.10. Rest of Asia Pacific
    • 18.4. China Digital Therapeutics (DTX) Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Therapeutic Application
      • 18.4.3. Product Type
      • 18.4.4. Sales Channel
      • 18.4.5. Prescription Type
      • 18.4.6. Patient Age Group
      • 18.4.7. Reimbursement Model
      • 18.4.8. Delivery Mode
      • 18.4.9. Technology
      • 18.4.10. End-Users
    • 18.5. India Digital Therapeutics (DTX) Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Therapeutic Application
      • 18.5.3. Product Type
      • 18.5.4. Sales Channel
      • 18.5.5. Prescription Type
      • 18.5.6. Patient Age Group
      • 18.5.7. Reimbursement Model
      • 18.5.8. Delivery Mode
      • 18.5.9. Technology
      • 18.5.10. End-Users
    • 18.6. Japan Digital Therapeutics (DTX) Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Therapeutic Application
      • 18.6.3. Product Type
      • 18.6.4. Sales Channel
      • 18.6.5. Prescription Type
      • 18.6.6. Patient Age Group
      • 18.6.7. Reimbursement Model
      • 18.6.8. Delivery Mode
      • 18.6.9. Technology
      • 18.6.10. End-Users
    • 18.7. South Korea Digital Therapeutics (DTX) Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Therapeutic Application
      • 18.7.3. Product Type
      • 18.7.4. Sales Channel
      • 18.7.5. Prescription Type
      • 18.7.6. Patient Age Group
      • 18.7.7. Reimbursement Model
      • 18.7.8. Delivery Mode
      • 18.7.9. Technology
      • 18.7.10. End-Users
    • 18.8. Australia and New Zealand Digital Therapeutics (DTX) Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Therapeutic Application
      • 18.8.3. Product Type
      • 18.8.4. Sales Channel
      • 18.8.5. Prescription Type
      • 18.8.6. Patient Age Group
      • 18.8.7. Reimbursement Model
      • 18.8.8. Delivery Mode
      • 18.8.9. Technology
      • 18.8.10. End-Users
    • 18.9. Indonesia Digital Therapeutics (DTX) Market
      • 18.9.1. Country Segmental Analysis
      • 18.9.2. Therapeutic Application
      • 18.9.3. Product Type
      • 18.9.4. Sales Channel
      • 18.9.5. Prescription Type
      • 18.9.6. Patient Age Group
      • 18.9.7. Reimbursement Model
      • 18.9.8. Delivery Mode
      • 18.9.9. Technology
      • 18.9.10. End-Users
    • 18.10. Malaysia Digital Therapeutics (DTX) Market
      • 18.10.1. Country Segmental Analysis
      • 18.10.2. Therapeutic Application
      • 18.10.3. Product Type
      • 18.10.4. Sales Channel
      • 18.10.5. Prescription Type
      • 18.10.6. Patient Age Group
      • 18.10.7. Reimbursement Model
      • 18.10.8. Delivery Mode
      • 18.10.9. Technology
      • 18.10.10. End-Users
    • 18.11. Thailand Digital Therapeutics (DTX) Market
      • 18.11.1. Country Segmental Analysis
      • 18.11.2. Therapeutic Application
      • 18.11.3. Product Type
      • 18.11.4. Sales Channel
      • 18.11.5. Prescription Type
      • 18.11.6. Patient Age Group
      • 18.11.7. Reimbursement Model
      • 18.11.8. Delivery Mode
      • 18.11.9. Technology
      • 18.11.10. End-Users
    • 18.12. Vietnam Digital Therapeutics (DTX) Market
      • 18.12.1. Country Segmental Analysis
      • 18.12.2. Therapeutic Application
      • 18.12.3. Product Type
      • 18.12.4. Sales Channel
      • 18.12.5. Prescription Type
      • 18.12.6. Patient Age Group
      • 18.12.7. Reimbursement Model
      • 18.12.8. Delivery Mode
      • 18.12.9. Technology
      • 18.12.10. End-Users
    • 18.13. Rest of Asia Pacific Digital Therapeutics (DTX) Market
      • 18.13.1. Country Segmental Analysis
      • 18.13.2. Therapeutic Application
      • 18.13.3. Product Type
      • 18.13.4. Sales Channel
      • 18.13.5. Prescription Type
      • 18.13.6. Patient Age Group
      • 18.13.7. Reimbursement Model
      • 18.13.8. Delivery Mode
      • 18.13.9. Technology
      • 18.13.10. End-Users
  • 19. Middle East Digital Therapeutics (DTX) Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. Middle East Digital Therapeutics (DTX) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Therapeutic Application
      • 19.3.2. Product Type
      • 19.3.3. Sales Channel
      • 19.3.4. Prescription Type
      • 19.3.5. Patient Age Group
      • 19.3.6. Reimbursement Model
      • 19.3.7. Delivery Mode
      • 19.3.8. Technology
      • 19.3.9. End-Users
      • 19.3.10. Country
        • 19.3.10.1. Turkey
        • 19.3.10.2. UAE
        • 19.3.10.3. Saudi Arabia
        • 19.3.10.4. Israel
        • 19.3.10.5. Rest of Middle East
    • 19.4. Turkey Digital Therapeutics (DTX) Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Therapeutic Application
      • 19.4.3. Product Type
      • 19.4.4. Sales Channel
      • 19.4.5. Prescription Type
      • 19.4.6. Patient Age Group
      • 19.4.7. Reimbursement Model
      • 19.4.8. Delivery Mode
      • 19.4.9. Technology
      • 19.4.10. End-Users
    • 19.5. UAE Digital Therapeutics (DTX) Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Therapeutic Application
      • 19.5.3. Product Type
      • 19.5.4. Sales Channel
      • 19.5.5. Prescription Type
      • 19.5.6. Patient Age Group
      • 19.5.7. Reimbursement Model
      • 19.5.8. Delivery Mode
      • 19.5.9. Technology
      • 19.5.10. End-Users
    • 19.6. Saudi Arabia Digital Therapeutics (DTX) Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Therapeutic Application
      • 19.6.3. Product Type
      • 19.6.4. Sales Channel
      • 19.6.5. Prescription Type
      • 19.6.6. Patient Age Group
      • 19.6.7. Reimbursement Model
      • 19.6.8. Delivery Mode
      • 19.6.9. Technology
      • 19.6.10. End-Users
    • 19.7. Israel Digital Therapeutics (DTX) Market
      • 19.7.1. Country Segmental Analysis
      • 19.7.2. Therapeutic Application
      • 19.7.3. Product Type
      • 19.7.4. Sales Channel
      • 19.7.5. Prescription Type
      • 19.7.6. Patient Age Group
      • 19.7.7. Reimbursement Model
      • 19.7.8. Delivery Mode
      • 19.7.9. Technology
      • 19.7.10. End-Users
    • 19.8. Rest of Middle East Digital Therapeutics (DTX) Market
      • 19.8.1. Country Segmental Analysis
      • 19.8.2. Therapeutic Application
      • 19.8.3. Product Type
      • 19.8.4. Sales Channel
      • 19.8.5. Prescription Type
      • 19.8.6. Patient Age Group
      • 19.8.7. Reimbursement Model
      • 19.8.8. Delivery Mode
      • 19.8.9. Technology
      • 19.8.10. End-Users
  • 20. Africa Digital Therapeutics (DTX) Market Analysis
    • 20.1. Key Segment Analysis
    • 20.2. Regional Snapshot
    • 20.3. Africa Digital Therapeutics (DTX) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 20.3.1. Therapeutic Application
      • 20.3.2. Product Type
      • 20.3.3. Sales Channel
      • 20.3.4. Prescription Type
      • 20.3.5. Patient Age Group
      • 20.3.6. Reimbursement Model
      • 20.3.7. Delivery Mode
      • 20.3.8. Technology
      • 20.3.9. End-Users
      • 20.3.10. Country
        • 20.3.10.1. South Africa
        • 20.3.10.2. Egypt
        • 20.3.10.3. Nigeria
        • 20.3.10.4. Algeria
        • 20.3.10.5. Rest of Africa
    • 20.4. South Africa Digital Therapeutics (DTX) Market
      • 20.4.1. Country Segmental Analysis
      • 20.4.2. Therapeutic Application
      • 20.4.3. Product Type
      • 20.4.4. Sales Channel
      • 20.4.5. Prescription Type
      • 20.4.6. Patient Age Group
      • 20.4.7. Reimbursement Model
      • 20.4.8. Delivery Mode
      • 20.4.9. Technology
      • 20.4.10. End-Users
    • 20.5. Egypt Digital Therapeutics (DTX) Market
      • 20.5.1. Country Segmental Analysis
      • 20.5.2. Therapeutic Application
      • 20.5.3. Product Type
      • 20.5.4. Sales Channel
      • 20.5.5. Prescription Type
      • 20.5.6. Patient Age Group
      • 20.5.7. Reimbursement Model
      • 20.5.8. Delivery Mode
      • 20.5.9. Technology
      • 20.5.10. End-Users
    • 20.6. Nigeria Digital Therapeutics (DTX) Market
      • 20.6.1. Country Segmental Analysis
      • 20.6.2. Therapeutic Application
      • 20.6.3. Product Type
      • 20.6.4. Sales Channel
      • 20.6.5. Prescription Type
      • 20.6.6. Patient Age Group
      • 20.6.7. Reimbursement Model
      • 20.6.8. Delivery Mode
      • 20.6.9. Technology
      • 20.6.10. End-Users
    • 20.7. Algeria Digital Therapeutics (DTX) Market
      • 20.7.1. Country Segmental Analysis
      • 20.7.2. Therapeutic Application
      • 20.7.3. Product Type
      • 20.7.4. Sales Channel
      • 20.7.5. Prescription Type
      • 20.7.6. Patient Age Group
      • 20.7.7. Reimbursement Model
      • 20.7.8. Delivery Mode
      • 20.7.9. Technology
      • 20.7.10. End-Users
    • 20.8. Rest of Africa Digital Therapeutics (DTX) Market
      • 20.8.1. Country Segmental Analysis
      • 20.8.2. Therapeutic Application
      • 20.8.3. Product Type
      • 20.8.4. Sales Channel
      • 20.8.5. Prescription Type
      • 20.8.6. Patient Age Group
      • 20.8.7. Reimbursement Model
      • 20.8.8. Delivery Mode
      • 20.8.9. Technology
      • 20.8.10. End-Users
  • 21. South America Digital Therapeutics (DTX) Market Analysis
    • 21.1. Key Segment Analysis
    • 21.2. Regional Snapshot
    • 21.3. Central and South Africa Digital Therapeutics (DTX) Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 21.3.1. Therapeutic Application
      • 21.3.2. Product Type
      • 21.3.3. Sales Channel
      • 21.3.4. Prescription Type
      • 21.3.5. Patient Age Group
      • 21.3.6. Reimbursement Model
      • 21.3.7. Delivery Mode
      • 21.3.8. Technology
      • 21.3.9. End-Users
      • 21.3.10. Country
        • 21.3.10.1. Brazil
        • 21.3.10.2. Argentina
        • 21.3.10.3. Rest of South America
    • 21.4. Brazil Digital Therapeutics (DTX) Market
      • 21.4.1. Country Segmental Analysis
      • 21.4.2. Therapeutic Application
      • 21.4.3. Product Type
      • 21.4.4. Sales Channel
      • 21.4.5. Prescription Type
      • 21.4.6. Patient Age Group
      • 21.4.7. Reimbursement Model
      • 21.4.8. Delivery Mode
      • 21.4.9. Technology
      • 21.4.10. End-Users
    • 21.5. Argentina Digital Therapeutics (DTX) Market
      • 21.5.1. Country Segmental Analysis
      • 21.5.2. Therapeutic Application
      • 21.5.3. Product Type
      • 21.5.4. Sales Channel
      • 21.5.5. Prescription Type
      • 21.5.6. Patient Age Group
      • 21.5.7. Reimbursement Model
      • 21.5.8. Delivery Mode
      • 21.5.9. Technology
      • 21.5.10. End-Users
    • 21.6. Rest of South America Digital Therapeutics (DTX) Market
      • 21.6.1. Country Segmental Analysis
      • 21.6.2. Therapeutic Application
      • 21.6.3. Product Type
      • 21.6.4. Sales Channel
      • 21.6.5. Prescription Type
      • 21.6.6. Patient Age Group
      • 21.6.7. Reimbursement Model
      • 21.6.8. Delivery Mode
      • 21.6.9. Technology
      • 21.6.10. End-Users
  • 22. Key Players/ Company Profile
    • 22.1. 2Morrow
      • 22.1.1. Company Details/ Overview
      • 22.1.2. Company Financials
      • 22.1.3. Key Customers and Competitors
      • 22.1.4. Business/ Industry Portfolio
      • 22.1.5. Product Portfolio/ Specification Details
      • 22.1.6. Pricing Data
      • 22.1.7. Strategic Overview
      • 22.1.8. Recent Developments
    • 22.2. Akili Interactive
    • 22.3. Ayogo Health
    • 22.4. Better Therapeutics
    • 22.5. Big Health
    • 22.6. Biofourmis
    • 22.7. Canary Health
    • 22.8. Click Therapeutics
    • 22.9. Cognoa
    • 22.10. Happify Health
    • 22.11. Kaia Health
    • 22.12. Livongo Health (Teladoc Health)
    • 22.13. Mango Health
    • 22.14. Mindstrong Health
    • 22.15. Noom
    • 22.16. Omada Health
    • 22.17. Pear Therapeutics
    • 22.18. Propeller Health (ResMed)
    • 22.19. Proteus Digital Health
    • 22.20. Voluntis (now part of AstraZeneca)
    • 22.21. Welldoc
    • 22.22. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation